HCA opens £26m specialist oncology unit

HCA Healthcare UK has opened the doors to its latest investment in complex cancer care; a £26milion specialist complex haematology and oncology unit at HCA Healthcare UK at University College Hospital.

The investment is part of HCA UK’s longstanding partnership with University College Hospital, providing private patient care at HCA UK at UCH since 2006. It sees the transfer and expansion of inpatient capability into a specially designed state-of-the-art 43-bed unit in the new Grafton Way building. 

With the expertise and infrastructure to provide innovative cancer therapies including CAR-T Cell Therapy, TIL Therapy and Haematopoietic Stem Cell Transplants, the development builds on HCA UK’s reputation as the most comprehensive provider of cancer care in the independent sector, with the capability across its healthcare system to care for patients, no matter how complex their condition, from diagnosis through to treatment and supportive care.

The expansion of HCA UK at UCH will enable access to inpatient clinical trials delivered via HCA UK’s research arm, Sarah Canon Research Institute UK. 

The new unit has been designed and equipped to support the delivery of high-quality acute care and ensure the best possible patient experience. Features  include:

  • An eight-bedded, HEPA-filtered Advanced Cellular Therapy Unit- the optimal clinical environment for highly specialised treatments such as CAR-T Cell Therapy.
  • A JACIE accredited Haematopoietic Stem Cell Transplant Unit for bone marrow transplants.
  • Inpatient rooms with positive pressure lobbies to minimise the risk of infection for immunocompromised patients.
  • Direct access to a 10-bedded haematology oncology specialist consultant led Intensive Treatment Unit (ITU) for patients with complex needs.
  • A dedicated Isolation Unit which means patients with transmissible infections can continue to be cared for within the unit safely.

 

Day care and outpatient services for private patients will continue to be delivered at the UCH Macmillan Cancer Centre.

Claire Smith, CEO of HCA UK NHS Joint Ventures said: “I am delighted to be expanding our inpatient care at HCA UK at UCH, further enhancing our capability and capacity to provide high quality cancer care and leading-edge treatments. Every aspect of this development has been designed with patient care and experience at the fore. Features such as the Advanced Cellular Therapy and Hematopoietic Stem CellTransplant Units are demonstrative of the acute specialist care that we are uniquely positioned to provide at HCA Healthcare UK.

“This is another important milestone in our longstanding partnerships with the NHS, building on the 2021 investment in our theatres at The Christie Private Care and looking ahead to our exciting new development with University Hospitals Birmingham.”

Latest Issues

IDSc Annual Conference 2024

Hilton Birmingham Metropole Hotel
26th - 27th November 2024

IV Forum 2024

Birmingham Conference & Events Centre (BCEC)
Wednesday 4th December 2024

The AfPP Roadshow - Leeds

TBA, Leeds
7th December 2024

Decontamination and Sterilisation 2025 Conference and Exhibition

The National Conference Centre, Birmingham
11th February 2025

The Fifth Annual Operating Theatres Show 2025

Kia Oval, London
11th March 2025, 9:00am - 4:00pm

Infection Prevention and Control 2025 Conference and Exhibition

The National Conference Centre, Birmingham
29th – 30th April 2025